
November 10, 2017 - By Henry Gaston
The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) hit a new 52-week low and has $32.37 target or 8.00 % below today’s $35.19 share price. The 7 months bearish chart indicates high risk for the $85.44B company. The 1-year low was reported on Nov, 10 by Barchart.com. If the $32.37 price target is reached, the company will be worth $6.84B less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 3.93 million shares traded. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since November 10, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.Among 15 analysts covering GlaxoSmithKline (NYSE:GSK), 6 have Buy rating, 1 Sell and 8 Hold. Therefore 40% are positive. GlaxoSmithKline had 23 analyst reports since September 8, 2015 according to SRatingsIntel. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Neutral” rating given on Monday, October 12 by JP Morgan. As per Tuesday, September 8, the company rating was upgraded by Bank of America. Jefferies upgraded the stock to “Buy” rating in Thursday, July 14 report. The stock has “Buy” rating by Berenberg on Friday, May 26. BNP Paribas downgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Wednesday, September 14 to “Underperform” rating. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Buy” rating given on Monday, December 7 by Argus Research. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) earned “Neutral” rating by J P Morgan Chase Co on Friday, June 16. The firm has “Neutral” rating by JP Morgan given on Wednesday, April 26. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Buy” rating given on Thursday, October 20 by Investec. Morgan Stanley downgraded the stock to “Underweight” rating in Friday, September 8 report.GlaxoSmithKline plc is a global healthcare company. The company has market cap of $85.44 billion. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. It has a 28.17 P/E ratio. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



(adsbygoogle = window.adsbygoogle || []).push({});
